Up to 60% off Profit Pro - Limited to first 500 users
Black Friday Sale
60% off Profit Pro - Limited to first 500 users
Pfizer Inc
PFE · NYSE24.80
24.80
USD-0.29-1.18%Date
Tickers
Headline
Source
Pfizer names oncology chief and company veteran Boshoff as chief scientific officer
MarketWatch
Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS
MarketWatch
Pfizer CEO says he welcomes good ideas as Starboard ups pressure on company
CNBC
Pfizer tops earnings estimates, hikes full-year guidance as Covid products help sales - CNBC
CNBC
FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease - CNBC
CNBC
Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment
MarketWatch
Pfizer former executives exit activist drive (NYSE:PFE) - Seeking Alpha
Seeking Alpha
Pfizer threatened to sue renegade executives prior to activist schism, Starboard's Smith says - CNBC
CNBC
Former Pfizer CEO, finance chief step back from Starboard's activist campaign - CNBC
CNBC
Activist investor Starboard has informed Pfizer it has taken a stake - Business Insider
Business Insider
Starboard reportedly takes $1 billion stake in Pfizer, seeks changes
MarketWatch
Activist Starboard Value has $1 billion Pfizer stake, taps former executives for help, sources say - CNBC
CNBC
Activist Starboard takes $1B stake in Pfizer - WSJ
SeekingAlpha
Exclusive | Activist Starboard Value Takes $1 Billion Stake in Pfizer - The Wall Street Journal
The Wall Street Journal
Pfizer yanks sickle-cell treatment worldwide after possible link to deaths
MarketWatch
Pfizer says its experimental drug for deadly condition that causes appetite and weight loss in cancer patients shows positive trial results - CNBC
CNBC
Pfizer and Valneva report positive results in mid-stage trial of Lyme disease vaccine
MarketWatch
Pfizer-BioNTech’s COVID-19-and-flu combination drug meets 1 of 2 trial objectives
MarketWatch
Pfizer reports positive results in study of vaccine for immunocompromised adults at risk of severe RSV-related illness
MarketWatch
Pfizer announces positive results from late-stage trial of hemophilia A treatment
MarketWatch
Pfizer signals progress on obesity pill, boosting stock
MarketWatch
Pfizer moves forward with once-daily version of weight loss pill after setbacks
CNBC
Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline - CNBC
CNBC
Alnylam’s stock surges as heart drug vies with a Pfizer blockbuster
MarketWatch
Pfizer aims to save $1.5 billion by 2027 in first wave of new cost cuts
CNBC
AI-Driven Drug Discovery by Pfizer and Austrian Institute Set to Transform Healthcare
Cryptopolitan
Former Pfizer employee goes down for insider trading in COVID drug trial
Cryptopolitan
Pfizer closes Seagen acquisition
SeekingAlpha
Pfizer shares fall as 2024 revenue and profit forecast disappoints
CNBC
Seagen gains amid options trades, optimism for FTC approval for Pfizer deal
SeekingAlpha
Pfizer's twice-daily weight loss pill joins a long list of obesity drug flops - CNBC
CNBC
Pfizer pulls the plug on twice-daily obesity pill as study disappoints - Reuters
Reuters
Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects - CNBC
CNBC
Pfizer CFO reiterates Seagen closing expected later this year, early next year
SeekingAlpha
What are you waiting for?Start making profit today
©
2024
All rights reserved
Cart